Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection

The development of new immunosuppressive drugs for kidney transplantation resulted both in better short-term outcomes and in decreased metabolic, cardiovascular, and nephrotoxicity risk. Belatacept belongs to a new class of immunosuppressive drugs that selectively inhibits T-cell activation by preve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ippoliti, Giovanbattista, D’Armini, Andrea Maria, Lucioni, Marco, Marjieh, Mazen, Viganò, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468025/
https://www.ncbi.nlm.nih.gov/pubmed/23055693
http://dx.doi.org/10.2147/BTT.S27565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468025/
https://www.ncbi.nlm.nih.gov/pubmed/23055693
http://dx.doi.org/10.2147/BTT.S27565

Ejemplares similares